An interventional study of iTBS (intermittent theta-burst stimulation) in Depression, sponsored by Vastra Gotaland Region. Recruiting at 2 sites in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-25.
Sponsored by Vastra Gotaland Region · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 183 studies in Depression with a site in Sweden — 34 open to participants now, 47 under way, 1 of them phase 3. Depression · Sweden.
Among the 183 studies in Depression with a site in Sweden, this one is the 62nd largest by planned enrollment of the 156 interventional ones that give a count, is one of 20 that started in 2024, is one of 124 with no phase, reaches primary completion later than 32 of the 46 other live ones, and was the 142nd registered.
8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.
Browse Depression studies →34 of the 183 studies in Depression with a site in Sweden are open now. Recruiting first, the newest first:
Uppsala University · Sites in Sweden
Ages 18–55
Region Stockholm · Sites in Sweden
Vastra Gotaland Region · Sites in Sweden
Ages 18+
Linkoeping University · Sites in Sweden
Ages 18+
Region Skane · Sites in Sweden
Ages 18–75 · Healthy volunteers
A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →
Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
183 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 13 · Phase 3 11 · Phase 4 4
First in 1998; this study’s year is marked. 20 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 146 is above the median of 81 across 7,089 interventional studies indexed under Depression.
Median enrollment 113 across the 156 interventional studies, 140 across the 26 observational. Of the 122 that completed or were terminated, 10 (8%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 183 have an industry lead sponsor. The 10 most frequent:
Vastra Gotaland Region is the lead sponsor of 276 studies on the registry; 110 are open to participants now.
Vastra Gotaland Region has 6 studies filed under Depression — fewer than ten, so there is no comparison to draw.
9 of the studies in Depression with a site in Sweden that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06549777Monique PfaltzBody-oriented Psychotherapy for Individuals With a History of Child Maltreatment and Trauma-related Symptoms | 2026-11 |
| NCT06145555Karolinska InstitutetAcute Psychological Sleep Stabilisation for Patients Hospitalised With Depression | 2026-12 |
| NCT07078227Region SkaneLong-term Follow-up of Depressive Disorders in Psychiatric Care | 2026-12-31 |
| NCT06138678Vastra Gotaland RegionVGR Accelerated TMS Treatment for Depression | 2027-01-01 |
| NCT07706816Uppsala UniversityEvaluation of a Remote Behavioural Stress Recovery Intervention for Myocardial Infarction Patients Younger Than Fifty-five (BRIM-55): A Feasibility Study | 2027-01-31 |
Add all 9 to your calendar (.ics) → With an account.
Among the 183 studies in Depression with a site in Sweden, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Intermittent theta burst stimulation (iTBS), a variant of repetitive transcranial magnetic stimulation (rTMS), is a well documented method for treatment of depression.
The aim of the study is to assess the effect of an accelerated iTBS protocol compared to a routine iTBS protocol. In the accelerated protocol patients will receive 1200 pulses per session (2 sessions per day, 15 treatment days) and in the routine protocol patients will receive 600 pulses per session (1 session per day, 30 treatment days).
Participants (n = 146) will be recruited among patients referred to iTBS and randomized to treatment. Participants will be assessed by a psychiatrist, or a resident psychiatrist, prior to treatment to assure that they fulfill all inclusion criteria and non of the exclusion criteria. A psychiatrist, or a resident psychiatrist, will assess depressive symptoms 3 and 6 weeks after first day of treatment. Patients will complete self-rating questionnaires during screening, weekly for 6 weeks starting from the first day of treatment, and 6 months after end of treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Magnetic pulses of 120% of visual motor threshold applied in triplets of 50 Hz bursts, repeated at 5 Hz; 2 seconds on and 8 seconds off; 1200 pulses per session; total duration of 6 min 40 s over the left DLPFC (F3), given in 2 sessions per day (50 min interval) on 15 week days.
Device: iTBS (intermittent theta-burst stimulation)
Magnetic pulses of 120% of visual motor threshold applied in triplets of 50 Hz bursts, repeated at 5 Hz; 2 seconds on and 8 seconds off; 600 pulses per session; total duration of 3 min 20 s over the left DLPFC (F3), given in 1 session per day on 30 week days.
Device: iTBS (intermittent theta-burst stimulation)
The iTBS treatment is a type of rTMS (repetitive transcranial magnetic stimulation), delivered with MagPro R30 stimulator and a conventional cool-B65 coil. The iTBS treatment is applied to over the dorsolateral prefrontal cortex using a standardized measuring of the anatomical landmark F3 from the 10-20 positioning system. The coil is positioned with the handle at in a 45 degree angle from the midline. The centre of the butterfly is placed towards the patient head.
Difference in MADRS-S from baseline to three weeks after first iTBS treatment
The self-rating version of the Montgomery-Asberg Depression Rating Scale (MADRS-S) is a rating scale (0-54 points), where a higher score indicates worse depressive symptoms
Time frame: 3 weeks
Difference in MADRS-S from baseline to one week after first iTBS treatment
The self-rating version of the Montgomery-Asberg Depression Rating Scale (MADRS-S) is a rating scale (0-54 points), where a higher score indicates worse depressive symptoms
Time frame: 1 week
Difference in MADRS-S from baseline to two weeks after first iTBS treatment
The self-rating version of the Montgomery-Asberg Depression Rating Scale (MADRS-S) is a rating scale (0-54 points), where a higher score indicates worse depressive symptoms
Time frame: 2 weeks
Difference in MADRS-S from baseline to four weeks after first iTBS treatment
The self-rating version of the Montgomery-Asberg Depression Rating Scale (MADRS-S) is a rating scale (0-54 points), where a higher score indicates worse depressive symptoms
Time frame: 4 weeks
Difference in MADRS-S from baseline to five weeks after first iTBS treatment
The self-rating version of the Montgomery-Asberg Depression Rating Scale (MADRS-S) is a rating scale (0-54 points), where a higher score indicates worse depressive symptoms
Time frame: 5 weeks
Difference in MADRS-S from baseline to six weeks after first iTBS treatment
The self-rating version of the Montgomery-Asberg Depression Rating Scale (MADRS-S) is a rating scale (0-54 points), where a higher score indicates worse depressive symptoms
Time frame: 6 weeks
Difference in MADRS-S from baseline to six months after last iTBS treatment
The self-rating version of the Montgomery-Asberg Depression Rating Scale (MADRS-S) is a rating scale (0-54 points), where a higher score indicates worse depressive symptoms
Time frame: 6 months
Difference in QIDS-SR from baseline to one week after first iTBS treatment
The self-rating Quick Inventory of Depressive Symptomatology (QIDS-SR) is a rating scale (0-27 points), where a higher score indicates worse depressive symptoms
Time frame: 1 week
Difference in QIDS-SR from baseline to two weeks after first iTBS treatment
The self-rating Quick Inventory of Depressive Symptomatology (QIDS-SR) is a rating scale (0-27 points), where a higher score indicates worse depressive symptoms
Time frame: 2 weeks
Difference in QIDS-SR from baseline to three weeks after first iTBS treatment
The self-rating Quick Inventory of Depressive Symptomatology (QIDS-SR) is a rating scale (0-27 points), where a higher score indicates worse depressive symptoms
Time frame: 3 weeks
Difference in QIDS-SR from baseline to four weeks after first iTBS treatment
The self-rating Quick Inventory of Depressive Symptomatology (QIDS-SR) is a rating scale (0-27 points), where a higher score indicates worse depressive symptoms
Time frame: 4 weeks
Difference in QIDS-SR from baseline to five weeks after first iTBS treatment
The self-rating Quick Inventory of Depressive Symptomatology (QIDS-SR) is a rating scale (0-27 points), where a higher score indicates worse depressive symptoms
Time frame: 5 weeks
Difference in QIDS-SR from baseline to six weeks after first iTBS treatment
The self-rating Quick Inventory of Depressive Symptomatology (QIDS-SR) is a rating scale (0-27 points), where a higher score indicates worse depressive symptoms
Time frame: 6 weeks
Difference in QIDS-SR from baseline to six months after first iTBS treatment
The self-rating Quick Inventory of Depressive Symptomatology (QIDS-SR) is a rating scale (0-27 points), where a higher score indicates worse depressive symptoms
Time frame: 6 months
Difference in SDS from baseline to six weeks after first iTBS treatment
The Sheehan Disability Scale (SDS) is a self-rating assessment (0-30 points), where a higher score indicates more pronounced functional impairment
Time frame: 6 weeks
Difference in SDS from baseline to six months after first iTBS treatment
The Sheehan Disability Scale (SDS) is a self-rating assessment (0-30 points), where a higher score indicates more pronounced functional impairment
Time frame: 6 months
Difference in EQ-VAS from baseline to three weeks after first iTBS treatment
The EQ-5D visual analogue scale (EQ-VAS) is a self-rating assessment (VAS 0-100 points), where a higher (VAS) score indicates a higher health-related quality of life
Time frame: 3 weeks
Difference in EQ-VAS from baseline to six weeks after first iTBS treatment
The EQ-5D visual analogue scale (EQ-VAS) is a self-rating assessment (VAS 0-100 points), where a higher (VAS) score indicates a higher health-related quality of life
Time frame: 6 weeks
Difference in EQ-VAS from baseline to six months after first iTBS treatment
The EQ-5D visual analogue scale (EQ-VAS) is a self-rating assessment (VAS 0-100 points), where a higher (VAS) score indicates a higher health-related quality of life
Time frame: 6 months
Difference in CGI-S from baseline to three weeks after first iTBS treatment
The Clinical Global Impression - Severity scale (CGI-S) is a clinical rating scale (0-7 points), where a higher score indicates more severe symptoms
Time frame: 3 weeks
Difference in CGI-S from baseline to six weeks after first iTBS treatment
The Clinical Global Impression - Severity scale (CGI-S) is a clinical rating scale (0-7 points), where a higher score indicates more severe symptoms
Time frame: 6 weeks
Difference in CGI-I from baseline to three weeks after first iTBS treatment
The Clinical Global Impression - Improvement scale (CGI-I) is a clinical rating scale (0-7 points) of symptom improvement (lower score)/worsening (higher score) compared to baseline
Time frame: 3 weeks
Difference in CGI-I from baseline to six weeks after first iTBS treatment
The Clinical Global Impression - Improvement scale (CGI-I) is a clinical rating scale (0-7 points) of symptom improvement (lower score)/worsening (higher score) compared to baseline
Time frame: 6 weeks
Number of patients in remission three weeks after first iTBS treatment
A patient with a MADRS-S score of \< 10 is considered to be in remission
Time frame: 3 weeks
Number of patients in remission six weeks after first iTBS treatment
A patient with a MADRS-S score of \< 10 is considered to be in remission
Time frame: 6 weeks
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2024 (actual). Primary completion is estimated for Jan 2027, 35 months after the start.
Of 3,486 non-industry interventional studies with no phase under Depression, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 35 months is above that.
Counting every sponsor, half of 3,584 studies reached it within 21 months; a quarter within 9 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.